Chronic Kidney Disease News

Researchers identified the distance between a household and a supermarket as a risk factor for chronic kidney disease, hypertension and diabetes development.

Belimumab treatment and standard therapy caused greater kidney outcomes among East Asian patients with lupus nephritis compared with standard therapy alone.

Bayer has received FDA approval to update to the label for finerenone, a nonsteroidal mineralocorticoid receptor antagonist, according to a press release.

Exercise and consuming protein during hemodialysis does not compromise uremic toxin removal in patients with end-stage renal disease, according to data published in the Journal of Renal Nutrition.

Patients on hemodialysis who received the high-dose trivalent inactivated influenza vaccine showed a stronger seroresponse than those who received other vaccines, according to data published the American Journal of Kidney Diseases.

African Caribbean adults with type 1 diabetes have a higher risk for kidney function loss than those of other ethnicities, according to study findings published in Diabetes Care.

A subanalysis of the FIDELITY trial showed finerenone reduced risk for all-cause and CV mortality, including sudden cardiac death, compared with placebo in adults with type 2 diabetes and chronic kidney disease.

Routine coronary angiography with revascularization when appropriate did not reduce 5-year mortality risk in patients with advanced chronic kidney disease and ischemia compared with an initial strategy of medical therapy.

Children aged 6 to 17 years with chronic kidney disease experience increased arterial stiffness, as measured by pulse wave velocity, but it is not a factor that correlates with eGFR or disease progression.

Leflunomide is non-inferior to azathioprine in terms of safety and efficacy for lupus nephritis maintenance therapy, according to data published in the Annals of the Rheumatic Diseases.